We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
-7.14%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$300M
AUM Growth
+$46.5M
Cap. Flow
+$72.7M
Cap. Flow %
24.26%
Top 10 Hldgs %
100%
Holding
12
New
1
Increased
2
Reduced
–
Closed
4

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$19.5M
2
INVA icon
Innoviva
INVA
+$824K

Top Sells

Rank Stock Value
1
BIVV
Bioverativ Inc. Common Stock
BIVV
+$8.44M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$5.85M
3
VVUS
Vivus Inc
VVUS
+$2.88M
4
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$598K

Sector Composition

Rank Sector Weight
1 Healthcare 54.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
1
Biogen
BIIB
$30B
$104M 34.77%
383,858
+73,858
+24% +$19.5M
MDCO
2
DELISTED
Medicines Co
MDCO
$66.6M 22.23%
1,752,000
– –
INVA icon
3
Innoviva
INVA
$1.55B
$44.7M 14.92%
3,490,705
+65,705
+2% +$824K
NVLN
4
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$9.46M 3.16%
1,025,000
– –
ADXS
5
DELISTED
Advaxis Inc
ADXS
$2.2M 0.73%
22,612
– –
SEEL
6
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$1.64M 0.55%
13
– –
ABBV icon
7
AbbVie
ABBV
$443B
$725K 0.24%
10,000
– –
ITCI
8
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-360,000
Closed -$5.85M
AVEO
9
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
– –
-101,362
Closed -$598K
BIVV
10
DELISTED
Bioverativ Inc. Common Stock
BIVV
– –
-155,000
Closed -$8.44M
VVUS
11
DELISTED
Vivus Inc
VVUS
– –
-257,394
Closed -$2.88M

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, Sarissa Capital Management held 12 positions worth $300M, up 18% from $253M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sarissa Capital Management deployed $72.7M of net new capital in Q2 2017, opening 1 new position and adding to 2 existing holdings.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, down from 66% a quarter earlier.

On the sell side, the most notable exit was Bioverativ Inc. Common Stock, an estimated $8.44M sold.

  • Sarissa Capital Management added most to Biogen in Q2 2017, an estimated $19.5M increase.
  • Sarissa Capital Management fully exited Bioverativ Inc. Common Stock in Q2 2017, selling an estimated $8.44M.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $300M portfolio in Q2 2017.
  • Sarissa Capital Management opened 1 new position and closed 4 in Q2 2017.
  • Sarissa Capital Management's portfolio value rose 18% quarter-over-quarter to $300M.

Based on Sarissa Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.